20:33 , Dec 6, 2018 |  BC Innovations  |  Translation in Brief

Opening chromatin: long-term detriment?

An Institute for Research in Biomedicine team has shown increasing chromatin accessibility in cancer could promote tumor aggressiveness, not reduce tumor mutation burden (TMB) as previously thought. The findings, reported last month in Nature Cell...
02:11 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Pathways emerging from ASH

A survey of the emerging molecular targets at this year’s American Society of Hematology conference indicates that while harnessing the immune system to treat cancer remains a dominant interest, processes for tuning protein levels --...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
18:08 , Jul 10, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling A 10-gene signature in tumors could help predict survival in breast cancer. In 4,994 breast cancer patients, low tumors levels of a signature based on the expression of 10 genes -- including...
16:04 , Jun 7, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute lymphoblastic leukemia (ALL); acute myelogenous leukemia (AML); B cell lymphoma Cell culture and mouse studies identified an aminoquinoline-based dual DNMT1 / EHMT2 inhibitor that could help treat ALL, AML and diffuse large B...
20:03 , Apr 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Growth failure Cell culture, patent sample and mouse studies suggest inhibiting EHMT2 could help treat growth deficiencies and premature death associated with Prader-Willi syndrome, in which SNRPN and other genes are paternally deleted and...
03:45 , Apr 7, 2017 |  BC Innovations  |  Strategy

Pushing for progress in Prader-Willi

In the wake of the 2015 clinical failure of Zafgen Inc. ’s subcutaneous beloranib for obesity in Prader-Willi syndrome patients, the Foundation for Prader-Willi Research (FPWR) last year launched a five-year, $26 million strategic research...
07:00 , Sep 15, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Euchromatic histone-lysine N-methyltransferase 2 (EHMT2; G9a)

Cancer INDICATION: Colorectal cancer Patient sample, cell culture and mouse studies suggest inhibiting EHMT2 could help treat colorectal cancer. In samples from colorectal cancer patients, high primary tumor levels of EHMT2 were associated with large...
08:00 , Jan 23, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Euchromatic histone-lysine N-methyltransferase 2 (EHMT2; G9A) In vitro and mouse studies suggest inhibiting G9A-mediated serine-glycine synthesis could help treat cancer. G9A is overexpressed in...
07:00 , Mar 29, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Euchromatic histone-lysine N-methyltransferase 2 (EHMT2; G9A); DNA methyltransferase Cell culture and mouse studies suggest blocking both G9A histone methyltransferase...